| Name | Title | Contact Details |
|---|
At Senderra, Patients are people. It`s that simple. We are a specialty pharmacy, but that is where our work begins. We believe success lies in service to others. For this reason, we are dedicated to never losing sight of the people. We believe in the power of technology and data as catalysts to transform and improve processes. Technology is a tool to make our lives easier. For this reason, Senderra invests in our unique technology-driven platform in order to perform best at every turn. Finally, we believe in improved outcomes, no matter with whom we work. That includes Patients, Prescribers, Pharma and Payors. Improving outcomes means we strive to make the kinds of differences that matter.
Institutional Pharmacy Solutions is a Montgomery, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biopure Corporation is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Heron Therapeutics is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending the duration of action. The Company's lead product, SUSTOL™ (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its SUSTOL New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration during the fourth quarter of 2014. Heron Therapeutics' core Biochronomer technology, on which SUSTOL and its other products are based, consists of bioerodible polymers designed to release drugs over a defined period of time. The Company has completed over 100 in vivo and in vitro studies demonstrating that its Biochronomer technology is potentially applicable to a range of therapeutic areas, including prevention of nausea and vomiting, pain management, control of inflammation and treatment of ophthalmic diseases. Heron Therapeutics has also completed comprehensive animal and human toxicology studies that have established that its Biochronomer polymers are generally well tolerated. Furthermore, the Company's Biochronomer technology can be designed to deliver drugs over periods varying from days to several months. In addition to its lead drug candidate SUSTOL, Heron Therapeutics has a pipeline of other product candidates that use the Biochronomer technology.